Literature DB >> 9453072

Iontophoretic delivery of apomorphine. II: An in vivo study in patients with Parkinson's disease.

R van der Geest1, T van Laar, J M Gubbens-Stibbe, H E Boddé, M Danhof.   

Abstract

PURPOSE: Transdermal transport rates of the dopamine agonist R-apomorphine were determined in patients with idiopathic Parkinson's disease (IPD). Apomorphine was applied by iontophoresis at two current densities.
METHODS: In ten patients apomorphine was applied passively for one hour. Thereafter, in the first five patients, a current density of 250 microA.cm-2 was applied for one hour and a current density of 375 microA.cm-2 in the second group. The individual pharmacokinetic parameters were obtained separately following a 15-minute zero-order intravenous infusion of 30 micrograms.kg-1. Skin resistance was measured during current delivery. Current-induced irritation was measured by Laser Doppler Flowmetry (LDF). The pharmacodynamics were quantified by a unilateral tapping score. Qualitative clinical improvements (decreased tremor, rigidity or cramp) were also recorded.
RESULTS: In all patients increasing plasma concentrations of R-apomorphine were found during the interval of current application. The maximum concentrations that were attained were related to the applied current density: 1.3 +/- 0.6 ng.ml-1 at 250 microA.cm-2 and 2.5 +/- 0.7 ng.ml-1 at 375 microA.cm-2. When the current was switched off all concentrations returned to baseline values in about 90 minutes. By mathematical deconvolution of the profiles it was shown that steady-state fluxes were reached within the one-hour interval of current driven transport Steady-state fluxes were calculated to be 69 +/- 30 nmol.cm-2.h-1 at 250 microA.cm-2 and 114 +/- 34 nmol.cm-2.h-1 at 375 microA.cm-2. Individual drug input rates were inversely related to the overall resistance. Significantly elevated LDF values were found after patch removal, indicating mild current induced erythema. Only subtherapeutic plasma concentrations were obtained in all patients except for one.
CONCLUSIONS: The results show that current-dependent delivery of apomorphine is possible in vivo at acceptable levels of skin irritation. Excellent correlation was found between the calculated in vivo transport rates and the rates that were previously obtained in vitro.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9453072     DOI: 10.1023/a:1012152401715

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  18 in total

1.  Sublingual apomorphine in Parkinson's disease: a clinical and pharmacokinetic study.

Authors:  J L Montastruc; O Rascol; J M Senard; V Gualano; H Bagheri; G Houin; A Lees; A Rascol
Journal:  Clin Neuropharmacol       Date:  1991-10       Impact factor: 1.592

2.  Intranasal apomorphine: a new treatment in Parkinson's disease.

Authors:  R Kapoor; N Turjanski; J Frankel; B Kleedorfer; A Lees; G Stern; M Bovingdon; R Webster
Journal:  J Neurol Neurosurg Psychiatry       Date:  1990-11       Impact factor: 10.154

3.  Sublingual apomorphine and Parkinson's disease.

Authors:  A J Lees; J L Montastruc; N Turjanski; O Rascol; B Kleedorfer; H Peyro Saint-Paul; G M Stern; A Rascol
Journal:  J Neurol Neurosurg Psychiatry       Date:  1989-12       Impact factor: 10.154

4.  Blood flow measurements in skin and underlying tissues by microsphere method: application to dermal pharmacokinetics of polar nonelectrolytes.

Authors:  P Singh; M S Roberts
Journal:  J Pharm Sci       Date:  1993-09       Impact factor: 3.534

5.  Noninvasive investigation of human skin after in vivo iontophoresis.

Authors:  S Thysman; D Van Neste; V Préat
Journal:  Skin Pharmacol       Date:  1995

Review 6.  Assessment of extrapyramidal disorders.

Authors:  C D Marsden; M Schachter
Journal:  Br J Clin Pharmacol       Date:  1981-02       Impact factor: 4.335

7.  Assay of R-apomorphine, S-apomorphine, apocodeine, isoapocodeine and their glucuronide and sulfate conjugates in plasma and urine of patients with Parkinson's disease.

Authors:  R van der Geest; P Kruger; J M Gubbens-Stibbe; T van Laar; H E Bodde; M Danhof
Journal:  J Chromatogr B Biomed Sci Appl       Date:  1997-11-21

8.  Pharmacokinetics, enantiomer interconversion, and metabolism of R-apomorphine in patients with idiopathic Parkinson's disease.

Authors:  R van der Geest; T van Laar; P P Kruger; J M Gubbens-Stibbe; H E Boddé; R A Roos; M Danhof
Journal:  Clin Neuropharmacol       Date:  1998 May-Jun       Impact factor: 1.592

9.  Iontophoretic transdermal delivery of salicylic acid and lidocaine to local subcutaneous structures.

Authors:  P Singh; M S Roberts
Journal:  J Pharm Sci       Date:  1993-02       Impact factor: 3.534

10.  The iontophoresis of fentanyl citrate in humans.

Authors:  M A Ashburn; J Streisand; J Zhang; G Love; M Rowin; S Niu; J K Kievit; J R Kroep; M J Mertens
Journal:  Anesthesiology       Date:  1995-05       Impact factor: 7.892

View more
  9 in total

1.  Effect of elastic liquid-state vesicle on apomorphine iontophoresis transport through human skin in vitro.

Authors:  G L Li; M Danhof; J A Bouwstra
Journal:  Pharm Res       Date:  2001-11       Impact factor: 4.200

2.  Lontophoretic delivery of apomorphine in vitro: physicochemic considerations.

Authors:  G L Li; M Danhof; J A Bouwstra
Journal:  Pharm Res       Date:  2001-11       Impact factor: 4.200

3.  Compartmental modeling of transdermal iontophoretic transport II: in vivo model derivation and application.

Authors:  Akhmad Kharis Nugroho; Oscar Della-Pasqua; Meindert Danhof; Joke A Bouwstra
Journal:  Pharm Res       Date:  2005-03       Impact factor: 4.200

Review 4.  Transdermal treatment options for neurological disorders: impact on the elderly.

Authors:  Lorenzo Priano; Maria Rosa Gasco; Alessandro Mauro
Journal:  Drugs Aging       Date:  2006       Impact factor: 3.923

5.  Pretreatment with a water-based surfactant formulation affects transdermal iontophoretic delivery of R-apomorphine in vitro.

Authors:  Gai Ling Li; Meindert Danhof; Peter M Frederik; Joke A Bouwstra
Journal:  Pharm Res       Date:  2003-04       Impact factor: 4.200

Review 6.  Potential of transdermal drug delivery in Parkinson's disease.

Authors:  Ronald F Pfeiffer
Journal:  Drugs Aging       Date:  2002       Impact factor: 3.923

Review 7.  An overview of clinical and commercial impact of drug delivery systems.

Authors:  Aaron C Anselmo; Samir Mitragotri
Journal:  J Control Release       Date:  2014-04-18       Impact factor: 9.776

8.  Transdermal iontophoresis of rotigotine across human stratum corneum in vitro: influence of pH and NaCl concentration.

Authors:  Akhmad Kharis Nugroho; Gai Ling Li; Meindert Danhof; Joke A Bouwstra
Journal:  Pharm Res       Date:  2004-05       Impact factor: 4.200

9.  Polymeric nanoparticle system to target activated microglia/macrophages in spinal cord injury.

Authors:  Simonetta Papa; Raffaele Ferrari; Massimiliano De Paola; Filippo Rossi; Alessandro Mariani; Ilaria Caron; Eliana Sammali; Marco Peviani; Valentina Dell'Oro; Claudio Colombo; Massimo Morbidelli; Gianluigi Forloni; Giuseppe Perale; Davide Moscatelli; Pietro Veglianese
Journal:  J Control Release       Date:  2013-11-10       Impact factor: 9.776

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.